Marathon Sells Controversial Duchenne Drug for $140 Million, Fate of Lucrative Voucher Unclear
March 17, 2017
Marathon Pharmaceuticals is selling its controversial Duchenne muscular dystrophy drug, Emflaza, for $140 million, however it is unclear whether the company will drastically increase its profits by selling the priority review voucher it was rewarded for getting the drug approved. Key lawmakers have said Marathon gamed the PRV system, which is meant to incentivize research on rare diseases, and have asked the company to specify its plan for the voucher -- which could fetch hundreds of millions of dollars. Marathon's...
Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting as the Trump administration and congressional Republicans take on the dismantling and replacement of the Affordable Care Act.